Alpine Global Management’s Aclaris Therapeutics ACRS Stock Holding History

Alpine Global Management’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-15,340	Closed	-$38K	–	134
2024 Q4	$38K	Buy	+15,340	New	+$38.2K	0.01%	155
2024 Q3	–	Sell	-177,909	Closed	-$196K	–	164
2024 Q2	$196K	Buy	+177,909	New	+$209K	0.03%	311
2022 Q1	–	Sell	-20,528	Closed	-$298K	–	434
2021 Q4	$298K	Buy	+20,528	New	+$311K	0.04%	437
2021 Q1	–	Sell	-22,333	Closed	-$144K	–	307
2020 Q4	$144K	Buy	+22,333	New	+$94.2K	0.03%	142

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Alpine Global Management's ACRS Position: Q1 2025 in Review

Alpine Global Management sold out of Aclaris Therapeutics (ACRS) in Q1 2025, closing a stake of 15,340 shares — an estimated $38K sold.

Alpine Global Management first reported a position in ACRS in Q4 2020 and held it in 4 quarters. The position peaked at $298K in Q4 2021. 109 funds tracked by Wall St. Rank hold ACRS as of Q1 2025.

Alpine Global Management reported no remaining Aclaris Therapeutics position as of Q1 2025 after selling out during the quarter.
Alpine Global Management sold 15,340 Aclaris Therapeutics shares in Q1 2025, an estimated $38K.
Alpine Global Management first reported a position in Aclaris Therapeutics in Q4 2020 and held it in 4 quarters.
Alpine Global Management's Aclaris Therapeutics position peaked at $298K in Q4 2021.
109 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2025.

Based on Alpine Global Management's 13F filing for Q1 2025, filed 15 May 2025.